$TFX

TELEFLEX INC

1
0
0

No SEC Form 4 filings for $TFX in the last 30 days.

Med

Teleflex presents clinical data on UroLift and Barrigel products By Investing.com

Teleflex Incorporated announced new clinical data for its UroLift System and Barrigel rectal spacer at recent medical conferences. The UroLift study showed a significantly lower rate of catheterization compared to a competitor, while the Barrigel study indicated zero percent Grade 2+ toxicity at three years. Despite a planned divestiture of its Interventional Urology unit, Teleflex is expected to maintain profitability and stock value.

New Teleflex (NYSE: TFX) CEO to lead amid $1B buyback and debt plan

Teleflex Incorporated has appointed Jason Weidman as its new President and CEO, effective June 8, 2026. Weidman, formerly of Medtronic, will earn a $1 million base salary, a 125% target annual bonus, and a $7 million annual equity award target, along with substantial sign-on and relocation benefits. This leadership change comes as Teleflex plans a significant capital reallocation, including a $1 billion share buyback and an $800 million debt paydown following pending sale transactions.

Teleflex Nominates Director, Plans Share Buybacks and Board Changes

Teleflex Incorporated (NYSE: TFX) has nominated Michael J. Tokich as an independent director, announced plans for early share repurchases, and will implement board leadership changes, including Andrew A. Krakauer becoming chairman. The company also intends to form a Growth and Operating Committee to enhance operational execution and identify expansion opportunities. These actions are part of Teleflex's strategy to address its undervalued stock price and continue its divestiture transactions.